Synthesis, physicochemical and anticonvulsant properties of new N-4-arylpiperazin-1-yl amides of (2-aza-1,3-dioxospiro[4.4]non-2-yl)- and [4.5]dec-2-yl-propionic acid

Archiv der Pharmazie

Volumn 340, Issue 8, 2007, Pages 404-408

  Obniska, Jolanta ^a   Kaminski, Krzysztof ^a   Hondo, Lukasz ^a   Zejc, Alfred ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Anticonvulsant activity; N 4 arylpiperazin 1 yl 2 aza 1,3 dioxospiro 4.4 non 2 yl and 4.5 dec 2 yl propionamides; Pyrrolidine 2,5 diones

Indexed keywords

AMELTOLIDE; ANTICONVULSIVE AGENT; ETHOSUXIMIDE; IMIDAZOLE DERIVATIVE; N (4 PHENYLPIPERAZIN 1 YL) 2 AZA 1,3 DIOXOSPIRO[4.4]NON 2 YL PROPIONAMIDE; N (4 PHENYLPIPERAZIN 1 YL) 2 AZA 1,3 DIOXOSPIRO[4.5]DEC 2 YL PROPIONAMIDE; N 4 (2 CHLOROPHENYL)PIPERAZIN 1 YL 2 AZA 1,3 DIOXOSPIRO[4.5]DEC 2 YL PROPIONAMIDE; N 4 (2 FLUOROPHENYL)PIPERAZIN 1 YL 2 AZA 1,3 DIOXOSPIRO[4.4]NON 2 YL PROPIONAMIDE; N 4 (2 FLUOROPHENYL)PIPERAZIN 1 YL 2 AZA 1,3 DIOXOSPIRO[4.5]DEC 2 YL PROPIONAMIDE; N 4 (2 METHYLPHENYL)PIPERAZIN 1 YL 2 AZA 1,3 DIOXOSPIRO[4.4]NON 2 YL PROPIONAMIDE; N 4 (2 METHYLPHENYL)PIPERAZIN 1 YL 2 AZA 1,3 DIOXOSPIRO[4.5]DEC 2 YL PROPIONAMIDE; N 4 (3 CHLOROPHENYL)PIPERAZINE 1 YL 2 AZA 1,3 DIOXOSPIRO[4.4]NON 2 YL PROPIONAMIDE; N 4 (3 CHLORPHENYL)PIPERAZIN 1 YL 2 AZA 1,3 DIOXOSPIRO[4.5]DEC 2 YL PROPIONAMIDE; N 4 (3 METHOXYPHENYL)PIPERAZINE 1 YL 2 AZA 1,3 DIOXOSPIRO[4.5]DEC 2 YL PROPIONAMIDE; N,N CARBONYLDIIMIDAZOLE; PENTETRAZOLE; PHENYTOIN; PROPIONAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTRIC SHOCK; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; POLYMERIZATION; PRIORITY JOURNAL; SEIZURE;

ANIMALS; ANTICONVULSANTS; MALE; MICE; PIPERAZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34548074639     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200700038     Document Type: Article

References (17)

1. E. Estrada, A. Pena, Bioorg. Med. Chem. 2000, 8, 2755-2770.
2. S. Moreau, P. Coudert, C. Rubat, D. Vallee-Goyet, et al., Bioorg. Med. Chem. 1998, 6, 983-991.
3. D. A. Learmonth, J. Benes, A. Parada, D. Hainzl, et al., Eur. J. Med. Chem. 2001, 36, 227-236.
4. J. Obniska, A. Dzierzawska-Majewska, A. Zagorska, P. Zajdel, J. Karolak-Wojciechowska, Farmaco 2005, 60, 529-539.
5. K. Kaminski, J. Obniska, A. Zagorska, D. Maciag, Arch. Pharm. Chem. Life Sci. 2006, 339, 255-261.
6. J. Obniska, K. Kaminski, A. Zagorska, A. Dzierzawska-Majewska, J. Karolak-Wojciechowska, J. Flourine Chem. 2006, 127, 417-425.
7. J. Obniska, K. Kaminski, Acta Pol. Pharm - Drug Res. 2006, 63, 101-108.
8. J. Obniska, A. Zejc, J. Karolak-Wojciechowska, Farmaco 1999, 54, 423-429.
9. J. Obniska, A. Zagorska, Farmaco 2003, 58, 1227-1234.
10. J. Obniska, M. Kolaczkowski, A. J. Bojarski, B. Duszynska, Eur. J. Med. Chem. 2006, 41, 874-881.
11. J. Obniska, K. Kaminski, E. Tatarczynska, Pharmacol. Rep. 2006, 58, 207-214.
12. J. Obniska, A. Zejc, Acta Pol. Pharm - Drug Res. 2005, 62, 283-288.
13. J. Obniska, A. Zejc, Acta Pol. Pharm - Drug Res. 2003, 60, 383-387.
14. K. R. Scott, J. A. Moore, T. B. Zalusky, J. M. Nicholson, M. Lee J. Med. Chem. 1985, 28, 413-417.
15. A. Mondon, Tetrahedron 1963, 19, 911-917.
16. R. L. Krall, J. K. Penry, B. G. White, H. J. Kupferberg, E. A. Swinyard, Epilepsia 1978, 19, 409-428.
17. H. J. Kupferberg, Epilepsia 1989, 30 (suppl.), 51-56.